Takeda Pharmaceutical Company Limited (VIE:TKD)

Austria flag Austria · Delayed Price · Currency is EUR
24.75
-0.13 (-0.52%)
At close: Oct 3, 2025
-0.52%
Market Cap38.57B
Revenue (ttm)26.44B
Net Income (ttm)808.10M
Shares Outn/a
EPS (ttm)0.50
PE Ratio47.73
Forward PEn/a
Dividend1.17 (4.72%)
Ex-Dividend DateSep 29, 2025
Volumen/a
Average Volumen/a
Open24.69
Previous Close24.88
Day's Range24.69 - 24.77
52-Week Range23.91 - 28.57
Betan/a
RSI35.52
Earnings DateOct 30, 2025

About VIE:TKD

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, A... [Read more]

Industry Pharmaceutical Preparations
Founded 1781
Employees 47,455
Stock Exchange Vienna Stock Exchange
Ticker Symbol TKD
Full Company Profile

Financial Performance

In 2024, VIE:TKD's revenue was 4.58 trillion, an increase of 7.45% compared to the previous year's 4.26 trillion. Earnings were 107.93 billion, a decrease of -25.08%.

Financial numbers in JPY Financial Statements

News

There is no news available yet.